

Leif Stenke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10030218/publications.pdf>

Version: 2024-02-01

68
papers

1,895
citations

393982

19
h-index

264894

42
g-index

68
all docs

68
docs citations

68
times ranked

2882
citing authors

#	ARTICLE	IF	CITATIONS
1	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	7.7	292
2	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 612-621.	5.1	214
3	Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia. <i>Blood</i> , 2009, 114, 790-790.	0.6	124
4	Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?. <i>Journal of Clinical Oncology</i> , 2014, 32, 2821-2823.	0.8	122
5	Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. <i>Blood</i> , 2017, 129, 2384-2394.	0.6	113
6	Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. <i>Blood</i> , 2013, 122, 1284-1292.	0.6	110
7	First Global Consensus for Evidence-Based Management of the Hematopoietic Syndrome Resulting From Exposure to Ionizing Radiation. <i>Disaster Medicine and Public Health Preparedness</i> , 2011, 5, 202-212.	0.7	91
8	Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. <i>Annals of Internal Medicine</i> , 2016, 165, 161.	2.0	86
9	Literature Review and Global Consensus on Management of Acute Radiation Syndrome Affecting Nonhematopoietic Organ Systems. <i>Disaster Medicine and Public Health Preparedness</i> , 2011, 5, 183-201.	0.7	78
10	The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1181-1191.	1.9	71
11	Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 559-564.	2.0	58
12	Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. <i>British Journal of Haematology</i> , 2015, 169, 683-688.	1.2	49
13	Expression of mRNA encoding neurotrophins and neurotrophin receptors in human granulocytes and bone marrow cells—enhanced neurotrophin-4 expression induced by LTB4. <i>Journal of Leukocyte Biology</i> , 1998, 64, 228-234.	1.5	33
14	Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. <i>Bone Marrow Transplantation</i> , 2019, 54, 1764-1774.	1.3	33
15	Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells. <i>Blood</i> , 2014, 124, 812-812.	0.6	33
16	Elevated white blood cell synthesis of leukotriene C4 in chronic myelogenous leukaemia but not in polycythaemia vera. <i>British Journal of Haematology</i> , 1990, 74, 257-263.	1.2	32
17	Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. <i>European Journal of Haematology</i> , 2016, 97, 387-392.	1.1	31
18	Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). <i>Blood</i> , 2014, 124, 519-519.	0.6	30

#	ARTICLE	IF	CITATIONS
19	Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. <i>Haematologica</i> , 2017, 102, 1361-1367.	1.7	28
20	Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 4030-4038.	3.2	20
21	Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1543-1554.	1.2	20
22	Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. <i>Oncolmmunology</i> , 2019, 8, e1638210.	2.1	19
23	Large Granular Lymphocyte (LGL) Expansions Comprising Oligoclonal T Cell or NK Cell Populations in Dasatinib Treated Patients Are Associated with HLA-A*0201, CMV Reactivation and Enhanced Anti-Leukemic Control.. <i>Blood</i> , 2009, 114, 1123-1123.	0.6	17
24	Novel enzymatic abnormalities in AML and CML in blast crisis: elevated leucocyte leukotriene C4synthase activity paralleled by deficient leukotriene biosynthesis from endogenous substrate. <i>British Journal of Haematology</i> , 1998, 101, 728-736.	1.2	14
25	The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia. <i>European Journal of Haematology</i> , 2017, 98, 398-406.	1.1	14
26	Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register. <i>European Journal of Haematology</i> , 2017, 98, 57-66.	1.1	13
27	Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR – final report from AFTER-SKI. <i>Leukemia</i> , 2021, 35, 2416-2418.	3.3	13
28	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. <i>Blood</i> , 2010, 116, 2291-2291.	0.6	12
29	Disease Relapse After TKI Discontinuation In CML Is Related Both To Low Number and Impaired Function Of NK-Cells:Data From Euro-SKI. <i>Blood</i> , 2013, 122, 379-379.	0.6	12
30	Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38+ stem and progenitor cells in chronic myeloid leukemia. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 378-384.	1.0	11
31	Interferon β is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 502-508.	1.0	11
32	Successful tyrosine kinase inhibitor discontinuation outside clinical trials – data from the population-based Swedish chronic myeloid leukaemia registry. <i>British Journal of Haematology</i> , 2021, 193, 915-921.	1.2	9
33	Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. <i>PLoS ONE</i> , 2017, 12, e0171041.	1.1	7
34	Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study. <i>American Journal of Hematology</i> , 2022, 97, 421-430.	2.0	7
35	The acute radiation syndrome – need for updated medical guidelines. <i>Journal of Radiological Protection</i> , 2022, 42, 014004.	0.6	7
36	Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia. <i>JACC: CardioOncology</i> , 2020, 2, 123-126.	1.7	6

#	ARTICLE	IF	CITATIONS
37	Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorogenic effects on CML cells. <i>Cell Death and Disease</i> , 2021, 12, 875.	2.7	6
38	Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish Population-Based Registries. <i>Blood</i> , 2014, 124, 3134-3134.	0.6	6
39	The tyrosine kinase inhibitor nilotinib targets discoidin domain receptor 2 in calcific aortic valve stenosis.. <i>British Journal of Pharmacology</i> , 0, , .	2.7	5
40	Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 555-567.	1.0	4
41	Long-term tolerability and efficacy after initial PegIFN α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study. <i>European Journal of Haematology</i> , 2021, 107, 617-623.	1.1	4
42	Clonal Large Granular Lymphocyte (LGL) Expansion Associated with Dasatinib Therapy.. <i>Blood</i> , 2007, 110, 2938-2938.	0.6	4
43	Dasatinib Treatment Induces Fast and Deep Responses In Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients In Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006). <i>Blood</i> , 2013, 122, 4032-4032.	0.6	4
44	Increased Risk of Chronic Myeloid Leukemia Following Gastric Conditions Indicating Helicobacter pylori Infection: A Case-Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 151-156.	1.1	3
45	Mature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission. <i>Blood</i> , 2015, 126, 343-343.	0.6	3
46	Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy. <i>Blood</i> , 2008, 112, 573-573.	0.6	3
47	Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG. <i>Blood</i> , 2011, 118, 2520-2520.	0.6	2
48	Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38+ Stem Cell Level: Results From Randomized NordCML006 Study. <i>Blood</i> , 2011, 118, 784-784.	0.6	2
49	Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results. <i>Blood</i> , 2021, 138, 635-635.	0.6	2
50	To be (prepared) or not to be – that is hardly the question.. <i>Journal of Radiological Protection</i> , 0, , .	0.6	2
51	Mental health and psychosocial consequences linked to radiation emergencies increasingly recognised concerns. <i>Journal of Radiological Protection</i> , 2022, 42, 031001.	0.6	2
52	Gene Expression Analyses At Time Of Diagnosis Indicate Biomarkers Predictive Of Therapeutic Response In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2619-2619.	0.6	1
53	Mono/Oligoclonal T and NK Cells Are Common in Philadelphia Chromosome Positive (Ph+) Leukemia Patients at Diagnosis and Expand During Successful Tyrosine Kinase Inhibitor Therapy.. <i>Blood</i> , 2009, 114, 856-856.	0.6	1
54	Overall Survival and Adverse Events in 378 Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia - a Swedish Register-Based Nationwide Study. <i>Blood</i> , 2021, 138, 3750-3750.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Detection of Proteins Related to Therapeutic Outcome, Including Drug Resistance, in Acute Myeloid Leukemia Using Mass Spectrometry and Gel Based Proteomic Profiling.. Blood, 2005, 106, 2367-2367.	0.6	0
56	Gemtuzumab Ozogamicin Combined with Hyper-CVAD in Relapsed Refractory CD33-Positive Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 4572-4572.	0.6	0
57	Global Proteomics in AML: Using SELDI-TOF MS on Diagnostic Samples To Identify Spectra and Protein Biomarkers Indicative of Prognosis.. Blood, 2006, 108, 4436-4436.	0.6	0
58	Analysis of γ H2AX and NHEJ Signaling as Molecular Determinants for GOSensitivity in AML. Blood, 2008, 112, 4854-4854.	0.6	0
59	The Importance of CD33 Expression and Pro-Apoptotic Signalling for Gemtuzumab Ozogamicin-Induced Cytotoxic Effects on AML Cells. Blood, 2008, 112, 5041-5041.	0.6	0
60	Landmark Analyses of BCR-ABL Using ES-FISH Early After Start of Imatinib Treatment to Newly Diagnosed CMLcp Patients Predicts Longterm Clinical Outcome.. Blood, 2009, 114, 4269-4269.	0.6	0
61	Gene Array Biomarkers in Acute Myeloid Leukemia to Predict Remission Duration.. Blood, 2009, 114, 3466-3466.	0.6	0
62	Individualized Multidrug Resistance In Acute Myeloid Leukemia. Blood, 2010, 116, 2491-2491.	0.6	0
63	The Proportion of Ph+ CD34+CD38neg Leukemic Stem Cells in the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study. Blood, 2010, 116, 667-667.	0.6	0
64	Landmark Analysis of Imatinib Treatment in CML Chronic Phase: ES-FISH <10% Ph+ At 3 Months Associated with Better Cytogenetic Response and Improved Long-Term Event-Free Survival. Blood, 2011, 118, 1702-1702.	0.6	0
65	Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib. Blood, 2013, 122, 1485-1485.	0.6	0
66	Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib. Blood, 2013, 122, 2731-2731.	0.6	0
67	Leukemic Stem Cell Quantification Is Of Prognostic Value In Newly Diagnosed Patients In Chronic Phase Chronic Myeloid Leukemia (CML-CP) Receiving Nilotinib Therapy: Results From The ENEST1st Stem Cell Substudy. Blood, 2013, 122, 649-649.	0.6	0
68	Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study. Blood, 2015, 126, 4022-4022.	0.6	0